Evidence map›Paper›PMID 32466419›Full record

ArticleCancers2020

Liquid Biopsy Serial Monitoring of Treatment Responses and Relapse in Advanced Esophageal Squamous Cell Carcinoma.

Josephine Mun Yee Ko, Hoi Yan Ng, Ka On Lam, Keith Wan Hang Chiu, Dora Lai Wan Kwong, Anthony Wing Ip Lo, Jean Chrysei Wong, Roger Chia Wei Lin, Henry Chun Hung Fong, Jason Ying Ki Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Clinical utility and applicability of circulating tumor DNA testing in esophageal cancer: a systematic review and meta-analysis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2022
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Josephine Mun Yee KoDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Hoi Yan NgDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Ka On LamDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Keith Wan Hang ChiuDepartment of Diagnostic Radiology, University of Hong Kong, Hong Kong, China.ORCID 0000-0002-7930-1193
Dora Lai Wan KwongDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Anthony Wing Ip LoDivision of Anatomical Pathology, Queen Mary Hospital, Hong Kong, China.ORCID 0000-0002-9388-310X
Jean Chrysei WongDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Roger Chia Wei LinDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Henry Chun Hung FongDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Jason Ying Ki LiDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Wei DaiDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.
Simon LawDepartment of Surgery, University of Hong Kong, Hong Kong, China.ORCID 0000-0002-6518-5806
Maria Li LungDepartment of Clinical Oncology, University of Hong Kong, Hong Kong, China.ORCID 0000-0003-2559-3626

Funding

Health and Medical Research Fund 05160926Hong Kong Research Grants Council Theme-based Research Scheme Grant T12-701/17R
6 · The paper itself

Abstract

(1) Background: Early predictive markers to track treatment responses are needed for advanced esophageal squamous cell carcinoma (ESCC) patients. We examined the prognostication and risk stratification role of liquid biopsy serial monitoring for this deadly cancer. (2) Methods: Circulating tumor cells (CTCs) and plasma cell-free DNA (cfDNA) were isolated from 60 ESCC patients treated by chemotherapy (CT) at five serial timepoints: baseline (CTC1/cfDNA1), CT pre-cycle III (CTC2/cfDNA2), CT post-cycle IV, end of CT and relapse. (3) Results: In 45/57 ESCC patients with evaluable CTC counts at CT pre-cycle III, positive CTC2 (≥3 CTCs) is independently associated with response at interim reassessment and progression-free survival (PFS) in multivariate analysis. In 42/57 ESCC patients with changes of CTC1/CTC2 and cfDNA1/cfDNA2, patients categorized into four risk groups based on the number of favorable and unfavorable changes of CTC1/CTC2 and cfDNA1/cfDNA2, were independently associated with overall survival (OS) by multivariate analysis. (4) Conclusions: CTC counts at pre-cycle III are independently associated with response at interim reassessment and PFS. Combined changes of CTC counts and cfDNA levels from baseline to pre-cycle III are independently associated with OS. Longitudinal liquid biopsy serial monitoring provides complementary information for prediction and prognosis for CT responses in advanced ESCC.

Indexed as

advanced ESCCcell-free DNAchemotherapycirculating tumor cellsCTC enumerationearly predictionliquid biopsylongitudinal real-time monitoringnon-invasive biomarkerprognosis

Identifiers

PMID32466419
PMCPMC7352685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.